Avadel Pharmaceuticals (AVDL)
(Delayed Data from NSDQ)
$13.24 USD
+0.04 (0.30%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $13.24 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum D VGM
Brokerage Reports
0 items in cart
Avadel Pharmaceuticals PLC. [AVDL]
Reports for Purchase
Showing records 1 - 20 ( 47 total )
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
Street Misunderstanding That a Major LUMRYZ Risk Was Just Removed; Buy on Weakness
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
2Q24: LUMRYZ Steadily Rising; Commence Positive Cash Flows; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
1Q24: Unjustified Negative Stock Reaction; We Raise Our PT to $27
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
While LUMRYZ Launch Rises, Litigation Risk Falls; Raise PT to $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for AVDL 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
3Q23: Early LUMRYZ Patient Referrals and Successful Starts Bolsters our Bullish View; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
2Q23: LUMRYZ Patient Enrollment and Expanded Coverage Bolster Confidence in Revenue Ramp; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
LUMRYZ Launch Out of the Gates Faster Than We Expected; Raise to $21
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
LUMRYZ Gets Approval, Orphan Exclusivity, and Strong Label; Raise PT to $17.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
Incremental LUMRYZ De-Risking Ahead of Potential Final Approval by May; PT to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
2023 Top Pick; See Substantial Upside on LUMRYZ Approval Within Months
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
HCW 2023 Top Picks: Seize the Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
Early Thanksgiving With Rapid Court Ruling to Remove REMS Patent Blocking Lumryz Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
District Court Hearing Has Us Optimistic For De-listing of Patent Holding Up Lumryz Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
2Q22: FT218 Tentative Approval In Hand; We Assume 2H23 Launch, But Potential 2H22 Legal Catalysts Could Accelerate
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
Working to Secure FT218 Final Approval Earlier Than Mid-2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
Delay for Patent Certification Is No Game-Changer; Selloff Extremely Overdone; Lower PT to $13 But Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
FT218 NDA Clarity Expected This Month; We Still Project Approval Assuming No Orphan Exclusivity Block; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
FT218 FDA Decision May Be Very Close; We Still Believe There Should Be No Orphan Exclusivity Roadblock; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
Still Awaiting FT218 FDA Decision Post PDUFA; Remain Optimistic Not Blocked by Competitor Exclusivity; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O